No FDA-Approved Medications for ARFID; Psychotherapy is First-Line Treatment
There are currently no pharmacologic treatments specifically recommended or FDA-approved for Avoidant/Restrictive Food Intake Disorder (ARFID). The 2023 American Psychiatric Association practice guidelines for eating disorders do not include any medication recommendations for ARFID, focusing instead on psychotherapy as the primary treatment modality 1.
Primary Treatment Approach
The evidence strongly supports psychotherapy as the cornerstone of ARFID treatment, not medication:
- Family-based treatment (FBT-ARFID) is superior to individual therapy for promoting weight gain in underweight children ages 6-12, particularly those with more severe ARFID symptoms 2
- Cognitive-behavioral therapy (CBT) adaptations show promise for ARFID treatment 3
- Treatment should involve a multidisciplinary team incorporating medical, psychiatric, psychological, and nutritional expertise 1
Off-Label Medication Use: Limited Evidence
While no medications are guideline-recommended, emerging research suggests potential off-label options when psychotherapy alone is insufficient:
Atypical Antipsychotics (Primarily Risperidone)
- A 2025 retrospective study of 21 children showed significant weight gain (9.66 kg), height gain (10.23 cm), and BMI increase (2.55 kg/m²) over 18 months with atypical antipsychotics 4
- Adverse effects were minimal with no discontinuations due to side effects 4
- Critical caveat: This is retrospective, uncontrolled data from a single center—not high-quality evidence
Mirtazapine
- Case reports describe successful use in combination with family-based therapy and partial hospitalization 5
- No controlled trial data available
Clinical Algorithm
When considering pharmacotherapy for ARFID:
First: Implement evidence-based psychotherapy (FBT-ARFID for children with involved caregivers, CBT adaptations for others) 2, 3
If inadequate response after 6+ months of psychotherapy and significant medical/nutritional compromise persists:
Monitor closely: Weight, height, BMI, metabolic parameters, and medication side effects
Treat co-occurring conditions: If anxiety, depression, or other psychiatric disorders are present and contributing to food avoidance, treat these with appropriate evidence-based medications for those specific conditions
Important Caveats
- The medication evidence for ARFID is extremely limited—mostly retrospective case series and case reports, not randomized controlled trials
- Unlike bulimia nervosa (where fluoxetine is recommended) or binge-eating disorder (where lisdexamfetamine or antidepressants are suggested), ARFID has no comparable medication evidence base 1
- Any medication use should be considered adjunctive to psychotherapy, never as monotherapy
- The mechanism by which atypical antipsychotics might help ARFID (appetite stimulation, reduced anxiety around eating) differs fundamentally from their use in other eating disorders 4
In real-world practice, prioritize intensive psychotherapy and nutritional rehabilitation before considering off-label medications, and only use medications when medical stability is at risk despite adequate psychotherapeutic intervention.